HOME       Contact Us      Hire Us       Domestic Airlines        Railway Enquiry     Railway Booking     Hotels Abroad
NEIGHBOURS CALLING:      Dubai      Malaysia     Nepal     Bhutan
indiatraveltimes.com
CORONAVIRUS CASUALTIES (Feb 28):- GLOBAL:- Total Cases: 11,44,64,297; Total Deaths: 25,39,067 Recovered: 9,00,08,036 BELGIUM:- Total Cases: 7,69,414; Total Deaths: 22,052 BRAZIL:- Total Cases: 1,05,17,232; Total deaths: 2,54,263 CANADA:- Total Cases: 8,64,196; Total Deaths: 21,960 CHINA:- Total Cases: 89,893 ; Total Deaths: 4,636 FRANCE:- Total Cases: 37,36,016; Total Deaths: 86,332 GERMANY:- Total Cases: 24,44,177 Total Deaths: 70,589 INDIA:- Total Cases: 1,10,96,731; Total Deaths: 1,57,087 INDONESIA:- Total Cases: 13,34,634; Total Deaths: 36,166 IRAN:- Total Cases: 16,31,169; Total Deaths: 60,073 ITALY:- Total Cases: 29,07,825; Total Deaths: 97,507 JAPAN:- Total Cases: 4,30,539; Total Deaths: 7,807 MEXICO:-Total Cases: 20,84,128; Total Deaths: 1,85,257 NETHERLANDS:- Total Cases: 10,84,021; Total Deaths: 15,543 PHILIPPINES:- Total Cases: 5,76,352; Total Deaths: 12,318 RUSSIA:- Total Cases: 42,46,079; Total Deaths: 86,122 S KOREA:- Total Cases: 89,676; Total Deaths: 1,603 SPAIN:-Total Cases: 31,88,553; Total Deaths: 69,142 SWEDEN:- Total Cases: 6,57,309 Total Deaths: 12,826 SWITZERLAND:-Total Cases: 5,54,932; Total Deaths: 9,966 UAE:- Total Cases: 3,91,524; Total Deaths: 1,221 UK:- Total Cases: 41,70,519; Total Deaths: 1,22,705; US:- Total Cases: 2,92,02,824; Total Deaths: 5,24,669 - India Travel Times.Com   [Estd: 1998]       * * *    Travel, More Travel, Travel Means A Million Things     * * *    
FDA issues Emergency Use Authorisation for Johnson & Johnson's single-dose covid vaccine
The advisory committee (VRBPAC) had earlier met, deliberated and quickly and unanimously recommended to the FDA to issue Emergency Use Authorisation (EUA) for Johnson & Johnson's single-dose covid vaccine (misreported by sections of New Media as the EUA). And the FDA, in a historic leap, late on Saturday issued the EUA as predicted by IndiaTravelTimes.com on Friday. The hassle-free vaccination will begin in the US immediately. The Federal Government says it's ready with 4 million doses, and another 100 million will come by April. A priority list for the immunisation will be out Sunday afternoon. The US is the worst hit by the pandemic, reporting over 5 lakh deaths.

WASHINGTON, Feb 27: The FDA late on Saturday approved Emergency Use Authorisation (EUA) for Johnson & Johnson's single-dose covid vaccine as reported by IndiaTravelTimes.com on Friday.

It will be the third vaccine to be administered to the Americans after Pfizer and Moderna. J&J scores over all other covid vaccines produced in the world so far in that it requires only single dose and that it can be stored and transported under normal refrigeration temperatures while Pfizer and Moderna require ultra cold storage and transportation, besides two doses.

On Friday, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) had met, deliberated and quickly and unanimously recommended to the FDA to issue emergency use authorisation (EUA) for the J&J vaccine.

In another of its pluses, J&J is also majorly claimed to inhibit asymptomatic infection, reducing the chances of transmission to a great extent, apart from preventing the disease in the inoculated. (But the FDA does not certify to this claim). There were also no reported cases of anaphylactic reactions following trial vaccination.

During the clinical trials, there were seven covid-related deaths in the placebo group while there were none in the vaccine group.

However, there were no sufficient trials to determine if the vaccine works in people over the age of 75. It hasn’t also been tested yet in children under the age of 18. (The FDA release excludes children under the age of 18, but does not exclude the elderly from vaccination).

The efficacy of the vaccine against moderate to severe covid across all geographic areas was 66.9% at least 14 days after the single-dose vaccination and 66.1% at least 28 days after vaccination.

"There were no specific safety concerns identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection," according to the data submitted by Johnson & Johnson.

The vaccine is claimed to work against the virus variants. The variants, which are more contagious, are behind majority of cases in several countries like South Africa and the UK.

The vaccine has a 72% efficacy rate in the US and a more than 68% rate in Brazil in protecting people from mild to severe illness. It offered nearly 86% protection against severe illness in the US and nearly 82% in South Africa and nearly 88% in Brazil.

The voting in the Advisory Committee (VRBPAC) was unanimous. Acting FDA Commissioner Dr. Janet Woodcock and Dr. Peter Marks, head of the FDA's vaccine decision, had said EUA would come quickly.

However, after the EUA, the US Centers for Disease Control and Prevention too have to okay before the vaccination begins. Its Advisory Committee on Immunization Practices (ACIP) has scheduled a meeting for Sunday. It will vote on Sunday afternoon, and instruct the details on distribution and identify priority groups. Thereafter, the CDC director, Dr Rochelle Walensky, will give the final go-ahead.

The Government is ready with 4 million doses and can start inoculation immediately. It had ordered 100 million doses of the vaccine.

Meanwhile, Dr Anthony Fauci, top covid adviser and director of the National Institute of Allergy and Infectious Diseases, has said one should not try to pick and choose vaccines but take what comes first.

The FDA release said, "The Janssen COVID-19 Vaccine is manufactured using a specific type of virus called adenovirus type 26 (Ad26). The vaccine uses Ad26 to deliver a piece of the DNA, or genetic material, that is used to make the distinctive “spike” protein of the SARS-CoV-2 virus. While adenoviruses are a group of viruses that are relatively common, Ad26, which can cause cold symptoms and pink eye, has been modified for the vaccine so that it cannot replicate in the human body to cause illness. After a person receives this vaccine, the body can temporarily make the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2."

However, significantly, it cautioned, "At this time, data are not available to determine how long the vaccine will provide protection, nor is there evidence that the vaccine prevents transmission of SARS- CoV-2 from person to person."

Previous Files
ARCHIVES



Neighbours
Calling

Bhutan
Nepal
Malaysia
Dubai

Dalai Lama discharged from hospital in New Delhi
Fashion & Lifestyle
Yoga & Asanas
Fairs, Festivals & Melas
Religion & Cult
Pilgrimage
Art & Culture
History, Legends & Mythology
Ayurveda
Free Ayurveda Consultation
ARCHIVES
A Window On India
Fashion & Lifestyle
Yoga & Asanas
Fairs, Festivals & Melas
Religion & Cult
Pilgrimage
Art & Culture
History, Legends & Mythology
Ayurveda
News (Archives)
Travel News
Travel News Archives
Travel News Index

Custom Search